BTK and mantle cell lymphoma: The appearance of the BTK inhibitors has dramatically improved the treatment of several B-cell malignancies, such as marginal zone lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and mantle cell lymphoma (MCL) [2,3,4].